Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Conditions

Breast Neoplasms 7244 Neoplasms 4539 Prostatic Neoplasms 3489 Colorectal Neoplasms 2940 Carcinoma, Non-Small-Cell Lung 2831 Lung Neoplasms 2547 Leukemia, Myeloid, Acute 1982 Pancreatic Neoplasms 1874 Multiple Myeloma 1811 Carcinoma, Hepatocellular 1733 Neoplasm Metastasis 1585 Stomach Neoplasms 1502 Lymphoma 1457 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1435 Head and Neck Neoplasms 1435 Brain Neoplasms 1373 Melanoma 1348 Ovarian Neoplasms 1342 Leukemia 1303 Rectal Neoplasms 1270 Recurrence 1255 Colonic Neoplasms 1204 Glioblastoma 1138 Uterine Cervical Neoplasms 1096 Lymphoma, Non-Hodgkin 1066 Leukemia, Lymphocytic, Chronic, B-Cell 989 Esophageal Neoplasms 965 Lymphoma, Follicular 936 Lymphoma, Large B-Cell, Diffuse 932 Squamous Cell Carcinoma of Head and Neck 921

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 HMPL-013 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Interventional × Fruquintinib × Clear all

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Unknown

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡